Hayden E. Klein

Marilyn Glassberg, MD, emphasizes the need for improved community education and highlights promising new drug pathways for idiopathic pulmonary fibrosis (IPF).

Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.

Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s both cost-effective and life-saving.

Researchers found a 30% increased risk of cardiovascular events in patients whose diagnosis was delayed by more than a year after an elevated blood pressure reading.

Findings underscore the potential limitations of using systemic inflammatory indices like the Dietary Inflammatory Index and Systemic Immune-Inflammation Index to assess organ-specific conditions.

Many patients value conversations with their rheumatologists and oncologists more than just reading information from a website.

Participants performed touchscreen-based reaching tasks while wearing wireless motion sensors, which recorded linear acceleration, angular velocity, and roll-pitch-yaw orientation at millisecond resolution.

The plaintiffs are seeking preliminary and permanent injunctions against recent COVID-19 vaccine policy changes and a declaratory judgment that the HHS secretary’s actions were unlawful.

Avoiding downstream testing ultimately makes it cheaper for whoever is footing the bill, says Merrill H. Stewart, MD, Ochsner Health.

Falls can often lead to reduced mobility or long-term disability in adults 65 and older, but there are strategies beyond exercise that can help these patients stay independent longer.

The lifestyle intervention included a whole-food plant-based diet, exercise, sleep, and stress management components.

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

Researchers said longitudinal studies are critical to refine and optimize the management of metabolic dysfunction–associated steatotic liver disease (MASLD).

Merrill Stewart, MD, Ochsner Health, says insufficient funding from CMS for graduate medical education (GME) limits the ability to expand cardiology fellowships and contributes to the nationwide physician shortage.

High infection rates among younger adults suggest they either delay routine dental care and only seek treatment when conditions become severe, or face more barriers.

Financial, family, and logistical challenges often lead patients to choose ongoing therapies over stem cell transplantation, says Mansi Shah, MD.

Researchers called for standardized health outcome descriptors to help bridge communication gaps in rheumatology care and improve shared decision-making.

In the M-ACCEL trial, HU6-induced weight loss was exclusively attributed to fat loss, with no statistically significant loss in lean muscle.

Mansi Shah, MD, explains how treatment sequencing and patient eligibility guide the use of these therapies in multiple myeloma.

Conversations between the patient and provider should focus on the stakes of antiobesity treatment and continuation, says Hamlet Gasoyan, PhD, Cleveland Clinic.

At 12 weeks, patients treated with ENV-101 showed statistically significant increases in lung volume compared with those receiving placebo.

Merrill H. Stewart, MD, Ochsner Health, explains how his practice takes advantage of downtime during cardiologist appointments to educate patients.

Compared with tezepelumab, solrikitug demonstrated unique epitope binding and superior potency across several assays.

Data from 2019 to 2023 show 9.2% of adults with obesity reported cost-related medication adherence.

Osteoarthritis leads the burden, projected to affect 50% of postmenopausal women by 2045.

Belimumab is now the first and only subcutaneous biologic therapy approved for at-home administration in pediatric lupus nephritis.

In a Cleveland Clinic cohort, patients who stopped treatment for obesity had smaller weight losses to start, making these gains easier to maintain, explained Hamlet Gasoyan, PhD.

There was no association observed between lower income and increased fibrosis among New York City residents with metabolic dysfunction-associated steatohepatitis (MASH).

Patients who see a cardiologist at least once a year are about 24% less likely to die in the following year.

Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite provider follow-up and efforts to manage side effects, says Hamlet Gasoyan, PhD, Cleveland Clinic.